In Wake Of Deals, Concert Is Latest To File For IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Lexington, Mass.-based Concert became the second company studying deuterium chemistry in the current pipeline for initial public offerings. It joins Auspex, which updated its filing this week, as did pain drug developer Cara.